PacBio Files Q1 2025 10-Q
Ticker: PACB · Form: 10-Q · Filed: 2025-05-12T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, reporting
Related Tickers: PACB
TL;DR
**PACB Q1 2025 10-Q FILED: Financials and operations update for the period ending March 31, 2025.**
AI Summary
Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment information are presented, reflecting the company's ongoing activities in the laboratory analytical instruments sector.
Why It Matters
This filing provides investors with the latest financial health and operational performance of Pacific Biosciences, a key player in genetic sequencing technology.
Risk Assessment
Risk Level: medium — The company operates in a highly competitive and rapidly evolving technological sector, which inherently carries significant market and innovation risks.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 20250512 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — Filer
- Menlo Park, CA (location) — Business and Mail Address
- 001-34899 (other) — SEC File Number
FAQ
What is the primary business of Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. is involved in the Laboratory Analytical Instruments sector, SIC code 3826.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 12, 2025.
What are the company's former names?
The company was formerly known as Pacific Biosciences of California Inc. and prior to that, Nanofluidics Inc.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
From the Filing
0001299130-25-000102.txt : 20250512 0001299130-25-000102.hdr.sgml : 20250512 20250512160853 ACCESSION NUMBER: 0001299130-25-000102 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25934842 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 10-Q 1 pacb-20250331.htm 10-Q pacb-20250331 0001299130 12-31 2025 Q1 false P20D http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment 0.02045157 0.0229885 0.0465116 http://fasb.org/us-gaap/2024#CostOfRevenue http://fasb.org/us-gaap/2024#CostOfRevenue xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:D pacb:customer 0001299130 2025-01-01 2025-03-31 0001299130 2025-04-30 0001299130 2025-03-31 0001299130 2024-12-31 0001299130 us-gaap:ProductMember 2025-01-01 2025-03-31 0001299130 us-gaap:ProductMember 2024-01-01 2024-03-31 0001299130 pacb:ServiceAndOtherMember 2025-01-01 2025-03-31 0001299130 pacb:ServiceAndOtherMember 2024-01-01 2024-03-31 0001299130 2024-01-01 2024-03-31 0001299130 us-gaap:CommonStockMember 2024-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001299130 us-gaap:RetainedEarningsMember 2024-12-31 0001299130 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001299130 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001299130 us-gaap:CommonStockMember 2025-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001299130 us-gaap:RetainedEarningsMember 2025-03-31 0001299130 us-gaap:CommonStockMember 2023-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001299130 us-gaap:RetainedEarningsMember 2023-12-31 0001299130 2023-12-31 0001299130 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001299130 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001299130 us-gaap:CommonStockMember 2024-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001299130 us-gaap:RetainedEarningsMember 2024-03-31 0001299130 2024-03-31 0001299130 pacb:DomesticCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-03-31 0001299130 pacb:DomesticCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001299130 pacb:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-03-31 0001299130 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001299130 us-gaap:FairValueInputsLevel2Member 2025-03-31 0001299130 us-gaap:FairValueInputsLevel3Member 2025-03-31 0001299130 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001299130 us-gaap:FairValueInputsLevel2Member 2024